41478-45-9

Basic information

• Product Name: diethyl 2-(2-(benzyloxy)ethyl)Malonate
• Synonyms: diethyl 2-(2-(benzyloxy)ethyl)Malonate;Propanedioic acid, [2-(phenylmethoxy)ethyl]-, diethyl ester
• CAS NO: 41478-45-9
• Molecular Formula: C₁₆H₂₂O₅
• Molecular Weight: 294.34288
• Mol File: 41478-45-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: diethyl 2-(2-(benzyloxy)ethyl)Malonate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl 2-(2-(benzyloxy)ethyl)Malonate(41478-45-9)
• EPA Substance Registry System: diethyl 2-(2-(benzyloxy)ethyl)Malonate(41478-45-9)

Safety Data

• Hazardous Substances Data: 41478-45-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Diethyl 2-(2-(benzyloxy)ethyl)malonate is used as a building block for the preparation of various pharmaceutical products. It is utilized in the synthesis of important intermediates, such as amino alcohols, which are widely employed in the development of medications.
Used in Agrochemical Industry:
diethyl 2-(2-(benzyloxy)ethyl)Malonate also serves as a key component in the creation of agrochemical products, contributing to the development of pesticides and other agricultural chemicals that are essential for crop protection and yield enhancement.
Used in Organic Synthesis:
Diethyl 2-(2-(benzyloxy)ethyl)malonate is used as a versatile reagent in organic synthesis, participating in a wide range of reactions such as esterification, alkylation, and condensation. Its unique properties make it suitable for the synthesis of complex molecules.
Used in Dye and Pigment Production:
Diethyl 2-(2-(benzyloxy)ethyl)malonate is used as a key starting material in the production of dyes, pigments, and other fine chemicals. Its involvement in these processes is crucial for creating a diverse array of colorants and specialty chemicals used across various industries.

Upstream product

• 17229-17-3 benzyl 2-chloroethyl ether 
• 996-82-7 sodium diethylmalonate 
• 1462-37-9 bromoethyl-2-benzyl ether 
• 105-53-3 diethyl malonate 
• 54555-84-9 benzyl iodoethyl ether 
• 622-08-2 2-Benzyloxyethanol 
• 58841-52-4 2-(benzyloxy)ethyl methanesulfonate 
• 96-49-1 [1,3]-dioxolan-2-one 
• 1208672-17-6 benzyl-2-bromoethyl ether 
• 4981-83-3 2-(Benzyloxy)ethyl p-toluenesulfonate 

Downstream Products

• 102012-71-5 3-(2-benzyloxy-ethyl)-4-hydroxy-8-methoxy-1-methyl-1H-quinolin-2-one 
• 10385-30-5 4-(benzyloxy)butanoic acid 
• 119951-31-4 diethyl 2-benzyloxyethyl(2-tetrahydropyran-2-yloxyethyl)malonate 
• 118602-97-4 ethyl 4-[(phenylmethyl)oxy]butanoate 
• 77661-80-4 2-(2-(benzyloxy)ethyl)propane-1,3-diol 
• 149876-89-1 2-(2-benzyloxyethyl)malonamide 
• 251922-46-0 2-(oxetan-3-yl)ethan-1-ol 
• 569678-81-5 3-(2-(benzyloxy)ethyl)oxetane 
• 569678-80-4 toluene-4-sulfonic acid 4-benzyloxy-2-hydroxymethyl-butyl ester 
• 167502-32-1 N,N'-di-t-butoxycarbonyl-2-(2-benzyloxyethyl)-1,3-diaminopropane 
• 130184-99-5 (+/-)-4-benzyloxy-2-(ethoxycarbonyl)butanoic acid 
• 130185-00-1 (+/-)-4-benzyloxy-2-(hydroxymethyl)butanoic acid 
• 130185-01-2 (+/-)-methyl 4-benzyloxy-2-(hydroxymethyl)butanoate 
• 119951-33-6 4-benzyloxy-2-(2-tetrahydropyran-2-yloxyethyl)butan-1-ol 

Relevant articles and documents

Guanidinium-Functionalized Flexible Azaproline Transporter for Efficient Intracellular Delivery of Proapoptotic Peptide and PDL1 Antisense Morpholino Oligo in Human Carcinoma Cells in Vitro

Cell-penetrating peptides (CPPs) are structurally diverse sophisticated tools endowed with high arginine content, amphipathicity, and well-adopted suitable secondary structures. Despite its capability of breaching the lipid barriers, CPP has major limitations such as in vivo metabolic instability, poor bioavailability, and reduced endosomal escape tendency, which are yet to be improved. In this context, we first have introduced a new class of cellular transporter having a guanidinium-functionalized δ-azaproline (δ-azp)-containing peptide where the δ-azp structurally resembles the proline amino acid having an additional N at the δ-position. This non-natural peptidic backbone was found to impart proteolytic stability, as reported earlier by our group. Herein, we report the synthesis of a flexible azaproline-tetraguanidinium transporter named FAT along with a revised scalable methodology for δ-azp compared to our previously reported procedure. FAT shows a random-coil-like structure as determined by CD spectroscopy, and is hence structurally different from the polyproline PPII helix. Direct translocation is predicted to be the possible mode of the cellular entrance of FAT into CHO cells when the Bodipy fluorophore is covalently attached as the cargo. Simultaneously, two other macromolecular therapeutics, e.g., proapoptotic domain peptide (PAD, a 14-mer peptide) and programmed death ligand 1 (PDL1) morpholino (a 25-mer antisense oligo), were successfully conjugated with FAT and delivered into human carcinoma cells, and their efficacy was analyzed by MTT assay and western blot technique, respectively. Having obtained promising results in internalizing different types of cargos, FAT could be envisaged as a potential drug delivery agent as an alternative to natural CPPs for future application.

Compound, liquid crystal composition, liquid crystal display element and liquid crystal display

The present invention relates to a compound, a liquid crystal composition, a liquid crystal display element, and a liquid crystal display. The compound is a compound represented by a formula I shown in the description. The liquid crystal composition of the present invention contains the compound represented by the formula I. The compound represented by the formula I has the advantages of good mutual solubility with other compounds and good UV resistance. As a reactive mesogen (RM), the compound has the advantages of good mutual solubility, high polymerization activity (less monomer residue), and strong binding ability. The compound can not only be used as a self-aligning agent for the liquid crystal compositions alone, but also can be used as a vertical alignment material for copolymerization with other RMs so as to be used as a self-aligning agent for the liquid crystal compositions in a PSA (polymer-supported alignment) and PS (polymer-stabilized) mode, the PI preparation process canbe avoided, the preparation process of the liquid crystal display element or liquid crystal display can be simplified, and the production efficiency can be improved.

Compounds, liquid crystal composition, liquid crystal display element and liquid crystal display

The invention relates to compounds, a liquid crystal composition, a liquid crystal display element and a liquid crystal display. The compounds are represented by a formula I shown in the description.The liquid crystal composition provided by the invention

LIQUID CRYSTAL MIXTURE AND LIQUID CRYSTAL DISPLAY

The invention relates to a compound of formula (I), wherein R11, R21, A11, A, Z, X11, X21, Y11, Y12, Sp11, Sp21, o and p have one of the meanings as given in claim 1. The invention further relates to method of production of a compound of formula (I), to the use of said compounds in LC media and to LC media comprising one or more compounds of formula (I). Further, the invention relates to a method of production of such LC media, to the use of such media in LC devices, and to LC device comprising a LC medium according to the present invention.The present invention further relates to a process for the fabrication such liquid crystal display and to the use of the liquid crystal mixtures according to the invention for the fabrication of such liquid crystal display.

METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula: and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

PIPERIDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula (I) and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR

The present invention relates to indole derivatives useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.

RADIOACTIVE FLUORINE LABELED COMPOUND

The present invention is a compound represented by the following formula (1) or a salt thereof. In the formula (1), R1 denotes a hydrogen atom, a methyl group, or a hydroxymethyl group, and n is an integer of 1 or 2.

APOPTOSIS IMAGING AGENTS BASED ON LANTIBIOTIC PEPTIDES

The present invention relates to radiopharmaceutical imaging in vivo of apoptosis. The invention provides imaging agents which target apoptotic cells via selective binding to the aminophospholipid phosphatidylethanolamine (PE), which is exposed on the surface of apoptotic cells. The radiopharmaceuticals comprise radiometal complexes of chelator conjugates of PE-binding peptides. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.

Bivalent inhibitors for disrupting protein surface-substrate interactions and for dual inhibition of protein prenyltransferases

Low-molecular-weight compounds that disrupt protein-protein interactions (PPIs) have tremendous potential applications as clinical agents and as chemical probes for investigating intracellular PPI networks. However, disrupting PPIs is extremely difficult due to the large, flat interfaces of many proteins, which often lack structurally defined cavities to which drug-like molecules could bind in a thermodynamically favorable manner. Here, we describe a series of bivalent compounds that anchor to the enzyme active site to deliver a minimally sized surface-binding module to the targeted surface involved in transient PPI with a substrate. These compounds are capable of significantly inhibiting enzymatic reactions involving protein surface-substrate interaction in the single-digit nanomole range. Inhibitors of farnesyltransferase (FTase), which possesses a negatively charged local area on its α-subunit, were designed by attaching a module derived from a branched monoamine-containing gallate to a conventional active-site-directed CVTM tetrapeptide using an alkyl spacer. A significant improvement in inhibitory activity (>200-fold) against farnesylation of the K-Ras4B peptide was observed when the gallate module was attached to the CVTM tetrapeptide. Furthermore, the bivalent compounds had submicromolar inhibitory activity against geranylgeranylation of the K-Ras4B peptide catalyzed by GGTase I, which has an a-subunit identical to that of FTase. The anchoring strategy we describe would be useful for designing a new class of PPI inhibitors as well as dual enzyme inhibitors targeting common surface structures.